| For: | Han K, Kim JH. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system. World J Gastroenterol 2015; 21(36): 10327-10335 [PMID: 26420959 DOI: 10.3748/wjg.v21.i36.10327] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v21/i36/10327.htm |
| Number | Citing Articles |
| 1 |
HoChong Gilles, Tonora Garbutt, Jasmine Landrum. Hepatocellular Carcinoma. Critical Care Nursing Clinics of North America 2022; 34(3) doi: 10.1016/j.cnc.2022.04.004
|
| 2 |
Yanling Bai, Zhigang Zheng, Mingmei Du, Hongwu Yao, Yunxi Liu, Jijiang Suo. Bloodstream Infection and Its Clinical Characteristics and Relevant Factors Associated with Interventional Therapy in a Large Tertiary Hospital: A Six Years Surveillance Study. BioMed Research International 2019; 2019 doi: 10.1155/2019/8190475
|
| 3 |
Haohao Lu, Bin Liang, Xiangwen Xia, Chuansheng Zheng. Efficacy and safety analysis of TACE + Donafenib + Toripalimab versus TACE + Sorafenib in the treatment of unresectable hepatocellular carcinoma: a retrospective study. BMC Cancer 2023; 23(1) doi: 10.1186/s12885-023-11535-5
|
| 4 |
Jian-Bo Zhang. Efficacy and safety of transcatheter arterial chemoembolization combined with sorafenib and sintilimab in the treatment of unresectable hepatocellular carcinoma. American Journal of Translational Research 2024; 16(12) doi: 10.62347/KNIV1276
|
| 5 |
Baljendra S. Kapoor, Giovanni Mauri, Jonathan M. Lorenz. Management of Biliary Strictures: State-of-the-Art Review. Radiology 2018; 289(3) doi: 10.1148/radiol.2018172424
|
| 6 |
Manal S. Fawzy, Eman A. Toraih. MicroRNA signatures as predictive biomarkers in transarterial chemoembolization‐treated hepatocellular carcinoma. Precision Medical Sciences 2021; 10(1) doi: 10.1002/prm2.12031
|
| 7 |
Haohao Lu, Chuansheng Zheng, Bin Liang, Xiangwen Xia, Hongjie Fan. Efficacy and safety analysis of TACE + PEI + lenvatinib compared with TACE + lenvatinib for the treatment of hepatocellular carcinoma with PVTT: a retrospective study. Frontiers in Oncology 2024; 14 doi: 10.3389/fonc.2024.1280837
|
| 8 |
Huajin Pang, Chen Tian, Genghan He, Di Zhang, Jinghong Yang, Qianbing Zhang, Ruiyuan Liu. NIR-absorbing Prussian blue nanoparticles for transarterial infusion photothermal therapy of VX2 tumors implanted in rabbits. Nanoscale 2021; 13(18) doi: 10.1039/D1NR01394G
|
| 9 |
Thomas Couri, Anjana Pillai. Goals and targets for personalized therapy for HCC. Hepatology International 2019; 13(2) doi: 10.1007/s12072-018-9919-1
|
| 10 |
Duk-Ju Kim, In Chul-Nam, Sung-Eun Park, Doo-Ri Kim, Jeong-Sub Lee, Bong-Soo Kim, Guk-Myung Choi, JeongJae Kim, Jung-Ho Won. Added Value of Cone-Beam Computed Tomography for Detecting Hepatocellular Carcinomas and Feeding Arteries during Transcatheter Arterial Chemoembolization Focusing on Radiation Exposure. Medicina 2023; 59(6) doi: 10.3390/medicina59061121
|
| 11 |
Qifan He, Yue Xiong, Xiaoyu Yang, Yihui Yu, Zhonghua Chen. Molecular subtyping combined with multiomics analysis to study correlation between TACE refractoriness and tumor stemness in hepatocellular carcinoma. Discover Oncology 2025; 16(1) doi: 10.1007/s12672-025-01955-z
|
| 12 |
S.S. Kim, T.W. Kang, M. Kim, M.W. Lee, S.K. Cho, Y.H. Paik, M.-J. Kim. Initial radiofrequency ablation failure for hepatocellular carcinoma: repeated radiofrequency ablation versus transarterial chemoembolisation. Clinical Radiology 2018; 73(2) doi: 10.1016/j.crad.2017.07.020
|
| 13 |
Ahmed W. Moawad, David Fuentes, Ahmed M. Khalaf, Katherine J. Blair, Janio Szklaruk, Aliya Qayyum, John D. Hazle, Khaled M. Elsayes. Feasibility of Automated Volumetric Assessment of Large Hepatocellular Carcinomas' Responses to Transarterial Chemoembolization. Frontiers in Oncology 2020; 10 doi: 10.3389/fonc.2020.00572
|
| 14 |
Jin Hyoung Kim, Ju Hyun Shim, Han Chu Lee, Kyu‐Bo Sung, Heung‐Kyu Ko, Gi‐young Ko, Dong Il Gwon, Jong Woo Kim, Young‐Suk Lim, Seong Ho Park. New intermediate‐stage subclassification for patients with hepatocellular carcinoma treated with transarterial chemoembolization. Liver International 2017; 37(12) doi: 10.1111/liv.13487
|
| 15 |
Junying Chen, Zeng Wang, Yuxiong Ding, Fei Huang, Weikang Huang, Ruilong Lan, Ruiqing Chen, Bing Wu, Lengxi Fu, Yunhua Yang, Jun Liu, Jinsheng Hong, Weijian Zhang, Lurong Zhang. Hypofractionated Irradiation Suppressed the Off-Target Mouse Hepatocarcinoma Growth by Inhibiting Myeloid-Derived Suppressor Cell-Mediated Immune Suppression. Frontiers in Oncology 2020; 10 doi: 10.3389/fonc.2020.00004
|
| 16 |
|
| 17 |
Xueying Zhang, Zijun He, Yucong Zhang, Jian Kong. Prediction of initial objective response to drug-eluting beads transcatheter arterial chemoembolization for hepatocellular carcinoma using CT radiomics-based machine learning model. Frontiers in Pharmacology 2024; 15 doi: 10.3389/fphar.2024.1315732
|
| 18 |
Peng Wang, Abraham S Moses, Chao Li, Song Chen, Xun Qi, Ke Xu, Hai-bo Shao, Xiang-jun Han. Prognosis factors of predicting survival in spontaneously ruptured hepatocellular carcinoma. Hepatology International 2022; 16(6) doi: 10.1007/s12072-022-10403-x
|
| 19 |
Chongkai Fang, Rui Luo, Ying Zhang, Jinan Wang, Kunliang Feng, Silin Liu, Chuyao Chen, Ruiwei Yao, Hanqian Shi, Chong Zhong. Hepatectomy versus transcatheter arterial chemoembolization for resectable BCLC stage A/B hepatocellular carcinoma beyond Milan criteria: A randomized clinical trial. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1101162
|
| 20 |
Felipe Nasser, Marcela Juliano Silva Cunha, Leonardo Guedes Moreira Valle, José Luiz Orlando. Vascular Surgery in Oncology. 2022; doi: 10.1007/978-3-030-97687-3_15
|
| 21 |
Leva Gorji, Hussein Aoun, Jeffrey Critchfield, Najeeb Al Hallak, Eliza W. Beal. Locoregional Therapy for Intrahepatic Cholangiocarcinoma: The Role of Intra-Arterial Therapies. Cancers 2023; 15(19) doi: 10.3390/cancers15194727
|
| 22 |
Simon Kashfi, Elizabeth Murdakhayev , Razia Rehmani, Shorabh Sharma. Post-Embolization Syndrome Complicated by Hypertensive Emergency and Severely Elevated Transaminases. Cureus 2021; doi: 10.7759/cureus.15446
|
| 23 |
Long Gao, Haili Yan, Shuang Zhu, Xiaochun Wang, Yan Tan, Jiangfeng Du, Duiping Feng, Hui Zhang, Zhanjun Gu. Targeted delivery of Bi2Se3 Nanoflowers to orthotopic liver tumor via transarterial infusion for enhanced microwave ablation sensibilization. Nano Today 2021; 41 doi: 10.1016/j.nantod.2021.101314
|
| 24 |
Xiao-Hui Wang, Wen-Bin Duan, Wei Liang, Hui Li, Xiao-Yan Xie, Shao-Qiang Li, Min-Shan Chen, Ping Liang, Xian-Hai Mao, Qun-Fang Zhou. Efficacy of radiofrequency ablation following transarterial chemoembolisation combined with sorafenib for intermediate stage recurrent hepatocellular carcinoma: a retrospective, multicentre, cohort study. eClinicalMedicine 2023; 56 doi: 10.1016/j.eclinm.2022.101816
|
| 25 |
Peijie Xia, Aibing Xu, Siyuan Tian, Honghua Huang, Miao Ouyang, Shengnan Huang, Hu Xu. Efficacy and Safety Analysis of Local-Systemic Combined Therapy Versus Systemic Therapy Alone in TACE-Resistant Hepatocellular Carcinoma Patients. Hepatitis Monthly 2026; 26(1) doi: 10.5812/hepatmon-168214
|
| 26 |
Yuanxun Yue, Zhizhong Ren, Ying Liu, Yuewei Zhang. Changes in the frequency of myeloid-derived suppressor cells after transarterial chemoembolization with gelatin sponge microparticles for hepatocellular carcinoma. Journal of Interventional Medicine 2019; 2(1) doi: 10.1016/j.jimed.2019.05.006
|
| 27 |
Min Hu, Ziyan Fan, Yu Han, Tian jiao Wang. Effect of Perioperative Comprehensive Nursing Intervention on Transcatheter Arterial Chemoembolization in Patients with Primary Hepatic Carcinoma. Evidence-Based Complementary and Alternative Medicine 2022; 2022 doi: 10.1155/2022/9000331
|
| 28 |
Yanzhao Zhou, Yi Yang, Bingyan Zhou, Zhengzheng Wang, Ruili Zhu, Xun Chen, Jingzhong Ouyang, Qingjun Li, Jinxue Zhou. Challenges Facing Percutaneous Ablation in the Treatment of Hepatocellular Carcinoma: Extension of Ablation Criteria. Journal of Hepatocellular Carcinoma 2021; doi: 10.2147/JHC.S298709
|
| 29 |
Mi Fan, Tingting Niu, Binwei Lin, Feng Gao, Bangxian Tan, Xiaobo Du. Prognostic value of preoperative serum ferritin in hepatocellular carcinoma patients undergoing transarterial chemoembolization. Molecular and Clinical Oncology 2024; 20(3) doi: 10.3892/mco.2024.2720
|
| 30 |
Dongjun Luo, Chen Wang, Beicheng Sun, Zhu Xu. Villin1 predicts survival and adjuvant TACE response in hepatocellular carcinoma. Cancer Genetics 2025; doi: 10.1016/j.cancergen.2025.11.003
|
| 31 |
Alireza Tojjari, James Yu, Anwaar Saeed. Immunotherapy and Radiation Therapy Combinatorial Approaches in Hepatocellular Carcinoma. Cancers 2024; 16(5) doi: 10.3390/cancers16051058
|
| 32 |
Xiaojing Song, Rangji Cai, Lili Wang, Fanghui Ding, Haixu Ni. A case report of a patient with stage IIIa hepatocellular carcinoma complicated by early gastric cancer. Frontiers in Oncology 2024; 14 doi: 10.3389/fonc.2024.1440171
|
| 33 |
欣 姚. Research Progress of TACE Combined with Sorafenib in the Treatment of HCC. Asian Case Reports in Oncology 2020; 9(04) doi: 10.12677/ACRPO.2020.94004
|
| 34 |
Juan Peng, Cui Yang, Jing Zheng, Ran Wang, Yi Zhou, Weicheng Wang, Lin Yang, Xiaoming Zhang, Nandong Miao, Yongjun Ren, Hao Xu, Xuli Min. Intravoxel Incoherent Motion Diffusion Weighted Imaging for the Therapeutic Response of Transarterial Chemoembolization for Hepatocellular Carcinoma. Journal of Cancer Therapy 2019; 10(07) doi: 10.4236/jct.2019.107048
|
| 35 |
Valentina Bianchi, Erida Nure, Carmen Nesci, Marco Maria Pascale, Gabriele Sganga, Salvatore Agnes, Giuseppe Brisinda. Bridge Therapy before Liver Transplant for Advanced Hepatocellular Carcinoma. Medicina 2024; 60(6) doi: 10.3390/medicina60061010
|
| 36 |
Kengo Ohta, Masashi Shimohira, Takuya Hashizume, Kazushi Suzuki, Yusuke Sawada, Yuta Shibamoto. Identification of the feeding arteries of hepatocellular carcinomas by performing dual arterial phase CT during pre-transarterial chemoembolization angiography. Abdominal Radiology 2019; 44(6) doi: 10.1007/s00261-019-01950-3
|
| 37 |
Jing Fei, Li-Wen Qi, Yuan Liu, Min Shu, Wen-Qiang Mo. Comparing transarterial chemoembolization alone to combined transarterial chemoembolization and radiofrequency ablation in primary hepatocellular carcinoma treatment. World Journal of Gastrointestinal Oncology 2025; 17(4): 102038 doi: 10.4251/wjgo.v17.i4.102038
|
| 38 |
Meng Jia, Jiang-Kun Jia, Jian Xu, Huan-Zhou Xue. Feasibility and Tolerability of Lenvatinib, Plus PD-1 Blockades for Patients with Unresectable Hepatocellular Carcinoma: A Retrospective Exploratory Study. Cancer Management and Research 2022; doi: 10.2147/CMAR.S372125
|
| 39 |
Lai Wei, Zeyu Wang, Niancai Jing, Yi Lu, Jili Yang, Hongyu Xiao, Huanyu Guo, Shoukun Sun, Mingjing Li, Daqing Zhao, Xiangyan Li, Wenxiu Qi, Yue Zhang. Frontier progress of the combination of modern medicine and traditional Chinese medicine in the treatment of hepatocellular carcinoma. Chinese Medicine 2022; 17(1) doi: 10.1186/s13020-022-00645-0
|
| 40 |
Hla‐Hla Thein, Wanrudee Isaranuwatchai, Yao Qiao, Kenny Wong, Gonzalo Sapisochin, Kelvin K. W. Chan, Eric M. Yoshida, Craig C. Earle. Cost‐effectiveness analysis of potentially curative and combination treatments for hepatocellular carcinoma with person‐level data in a Canadian setting. Cancer Medicine 2017; 6(9) doi: 10.1002/cam4.1119
|
| 41 |
Xiu-Ping Zhang, Shuai Xu, Ming-Gen Hu, Zhi-Ming Zhao, Zhao-Hai Wang, Guo-Dong Zhao, Cheng-Gang Li, Xiang-Long Tan, Rong Liu. Short- and long-term outcomes after robotic and open liver resection for elderly patients with hepatocellular carcinoma: a propensity score-matched study. Surgical Endoscopy 2022; 36(11) doi: 10.1007/s00464-022-09236-4
|
| 42 |
Feng Qi, Lingxiao Wang, Peixin Huang, Zhiying Zhao, Biwei Yang, Jinglin Xia. Time‑series clustering of cytokine expression after transarterial chemoembolization in patients with hepatocellular carcinoma. Oncology Letters 2019; doi: 10.3892/ol.2019.11209
|
| 43 |
Ziqiang Han, Faji Yang, Ye Zhang, Jianlu Wang, Qingqiang Ni, Huaqiang Zhu, Xu Zhou, Hengjun Gao, Jun Lu. Prognostic efficacy and prognostic factors of TACE plus TKI with ICIs for the treatment of unresectable hepatocellular carcinoma: A retrospective study. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.1029951
|
| 44 |
Soon Sun Kim, Ji Sun Nam, Hyo Jung Cho, Je Hwan Won, Jin Woo Kim, Jae‐Hoon Ji, Min Jae Yang, Joo Han Park, Choong‐Kyun Noh, Sung Jae Shin, Kee Myung Lee, Sung Won Cho, Jae Youn Cheong. Plasma micoRNA‐122 as a predictive marker for treatment response following transarterial chemoembolization in patients with hepatocellular carcinoma. Journal of Gastroenterology and Hepatology 2017; 32(1) doi: 10.1111/jgh.13448
|
| 45 |
Seyda Gunduz, Gia Saini, Nicole Segaran, Sailen Naidu, Indravadan Patel, Sadeer Alzubaidi, Rahmi Oklu. Radioembolization for Hepatocellular Carcinoma. Digestive Disease Interventions 2021; 5(03) doi: 10.1055/s-0041-1732304
|
| 46 |
Jing Li, Hai-Yan Shi, Min Zhou. Correlation between preoperative systemic immune inflammation index, nutritional risk index, and prognosis of radical resection of liver cancer. World Journal of Gastrointestinal Surgery 2023; 15(11): 2445-2455 doi: 10.4240/wjgs.v15.i11.2445
Abstract(858) |
Core Tip(739) |
Full Article(HTML)(2163)
|
Full Article (PDF)-564K(192)
|
Full Article with Cover (PDF)-823K(196)
|
Full Article (Word)-261K(41)
|
Full Article (XML)-111K(179)
|
Audio-965K(17)
|
Peer-Review Report-226K(135)
|
Answering Reviewers-39K(131)
|
Times Cited (11)
|
Total Visits (3742)
|
Open
|
| 47 |
|
| 48 |
Ling Li, Yicheng Zhang, Yang Zhou, Haijie Hu, Yizong Hu, Christos Georgiades, Hai‐Quan Mao, Florin M. Selaru. Quaternary nanoparticles enable sustained release of bortezomib for hepatocellular carcinoma. Hepatology 2022; 76(6) doi: 10.1002/hep.32584
|
| 49 |
Thi Tuyet Mai Nguyen, Cam Phuong Pham, Minh Phuong Vu. Neutrophil‑to‑lymphocyte ratio as a predictive marker for portal vein thrombosis in hepatocellular carcinoma. World Academy of Sciences Journal 2026; 8(3) doi: 10.3892/wasj.2026.459
|
| 50 |
Bojun Liu, Xue Yin, Wenying Qiao, Xiaoyan Ding, Caixia Hu. Prognostic model for predicting recurrence-free survival in HBV-related hepatocellular carcinoma patients after combined treatment: a multicenter study. Frontiers in Oncology 2026; 16 doi: 10.3389/fonc.2026.1760126
|
| 51 |
Pyeong Hwa Kim, Dong Il Gwon, Jong Woo Kim, Hee Ho Chu, Jin Hyoung Kim. The safety and efficacy of balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma refractory to conventional transcatheter arterial chemoembolization. European Radiology 2020; 30(10) doi: 10.1007/s00330-020-06911-9
|
| 52 |
Haohao Lu, Bin Liang, Xiangwen Xia, Chuansheng Zheng. Efficacy Analysis of PTCD + TACE vs PTCD + Apatinib in the Treatment of HCC with Obstructive Jaundice: A Retrospective Study. Anti-Cancer Agents in Medicinal Chemistry 2024; 24(17) doi: 10.2174/0118715206313132240712101607
|
| 53 |
Shu Feng, Ying Xuan, Hong Jin, Meng Cui, Xinyue Meng, Jun Liao, Jianwei Feng. Nanozyme for precision treatment of hepatocellular carcinoma. Materials Today Bio 2026; 37 doi: 10.1016/j.mtbio.2026.102840
|
| 54 |
Rao Fu, Fangjing Yu, Weiqi Wu, Juan Liu, Jia Li, Fangyue Guo, Lei Xu, Feng Wang, Xiaonan Cui. Bufalin enhances the killing efficacy of NK cells against hepatocellular carcinoma by inhibiting MICA shedding. International Immunopharmacology 2021; 101 doi: 10.1016/j.intimp.2021.108195
|
| 55 |
Bo Sun, Weihua Zhang, Lei Chen, Tao Sun, Yanqiao Ren, Licheng Zhu, Kun Qian, Chuansheng Zheng. The safety and efficacy of percutaneous ethanol injection in the treatment of tumor thrombus in advanced hepatocellular carcinoma with portal vein tumor thrombus. Abdominal Radiology 2022; 47(2) doi: 10.1007/s00261-021-03349-5
|
| 56 |
Lin Xu, Dongxu Zhao, Pengcheng Tian, Jiaan Ding, Zhengyu Jiang, Guanyin Ni, Zhongheng Hou, Caifang Ni. Development and Validation of a Prognostic Model for Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma Based on Preoperative Serum Prealbumin. Journal of Hepatocellular Carcinoma 2023; doi: 10.2147/JHC.S433245
|
| 57 |
Yasir M. Nouri, Jin Hyoung Kim, Hyun-Ki Yoon, Heung-Kyu Ko, Ji Hoon Shin, Dong Il Gwon. Update on Transarterial Chemoembolization with Drug-Eluting Microspheres for Hepatocellular Carcinoma. Korean Journal of Radiology 2019; 20(1) doi: 10.3348/kjr.2018.0088
|
| 58 |
Jonghoon Kim, Seung Joon Choi, Seung-Hak Lee, Ho Yun Lee, Hyunjin Park. Predicting Survival Using Pretreatment CT for Patients With Hepatocellular Carcinoma Treated With Transarterial Chemoembolization: Comparison of Models Using Radiomics. American Journal of Roentgenology 2018; 211(5) doi: 10.2214/AJR.18.19507
|
| 59 |
Jiwon Yang, Jihye Lim, Eun Hye Kim, Jihyun An, Danbi Lee, Han Chu Lee, Jin-Yong Jeong, Ju Hyun Shim. Prognostic Role of Short-Chain Fatty Acid-Producing Gut Microbiota and Gut Microbial Dynamics in Patients with Hepatocellular Carcinoma Receiving Chemoembolization: A Prospective Study. Journal of Hepatocellular Carcinoma 2025; doi: 10.2147/JHC.S537216
|
| 60 |
Niharika Dutta, Pankaj Gupta. Predicting Response to Transarterial Chemoembolization in Hepatocellular Carcinoma Using Machine Learning Models. Indian Journal of Radiology and Imaging 2026; 36(02) doi: 10.1055/s-0045-1809372
|
| 61 |
Ludovico Abenavoli, Maria Luisa Gambardella, Eugenia Passante, Giuseppe La Torre, Caterina Battaglia, Francesco Manti, Domenico Console, Francesco Luzza, Domenico Laganà. The evolving role of contrast-enhanced ultrasound in hepatocellular carcinoma: from diagnosis to therapeutic monitoring. Hepatoma Research 2026; doi: 10.20517/2394-5079.2025.39
|
| 62 |
Zhigang Fu, Xiaowei Li, Jiaming Zhong, Xiaoxia Chen, Kunkun Cao, Ning Ding, Li Liu, Xiaoli Zhang, Jian Zhai, Zengqiang Qu. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study. Hepatology International 2021; 15(3) doi: 10.1007/s12072-021-10184-9
|
| 63 |
Zhongren Xu, Yu Liu, Jiaqi Yang, Fuwei Li, Wukun Liu. Recent Advances of Metal Complexes in the Treatment of Hepatocellular Carcinoma. Journal of Medicinal Chemistry 2025; 68(1) doi: 10.1021/acs.jmedchem.4c01850
|
| 64 |
Henry Sutanto, Galih Januar Adytia, Elisa Elisa, Ummi Maimunah. Advances in transarterial chemoembolization for hepatocellular carcinoma: Integration with systemic therapies and emerging treatment strategies. Cancer Pathogenesis and Therapy 2026; 4(1) doi: 10.1016/j.cpt.2025.04.004
|
| 65 |
_ _, Oszkár Hahn, Attila Szijártó, Damján Pekli, András Fülöp, Bálint Kokas, Dávid Bárdos, Csilla András, Péter Bartek, István Battyáni, János Bezsilla, György Bodoky, Attila Bursics, Magdolna Dank, Zsófia Dankovics, Ákos Deák Pál, Kristóf Dede, Gyula Demeter, Attila Doros, Ibolyka Dudás, Zsófia Egyed, Róbert Farkas, Zsuzsanna Gerlei, Tamás Györke, Krisztina Hagymási, Oszkár Hahn, Erika Hitre, József Hőhn, Viktor Jancsik, Zsolt Káposztás, István Király, András Kiss, László Kóbori, Péter Kupcsulik, Gábor Lakatos, István Lázár, Tamás Lóderer, Endre Nagy, Attila Oláh, Péter Pajor, András Papp, Gabriella Pár, Mihály Patyánik, Damján Pekli, Ágota Petrányi, András Petri, László Piros, János Schuller, László Sikorszki, József Szabó, Eszter Székely, Attila Szijártó, Andrea Szombati, László Torday, Judit Tóth, Lajos Barna Tóth, Edit Dósa, László Harsányi, Zsolt Horváth, Gábor István, László Landherr, György Lázár, Gabriella Lengyel, József Lővey, László Mangel, Pál Maurovich Horváth, Balázs Nemes, András Palkó, Zsuzsa Schaff, Ferenc Szalay, Ákos Szűcs, András Vereczkei. A hepatocellularis carcinoma komplex kezelése.. Orvosi Hetilap 2022; 162(Supplement-2) doi: 10.1556/650.2021.32431
|
| 66 |
Guangfeng Zhang, Yongxing Yun, Chunming Lin, Huafeng Li, Fenglin Liu. Predictive Value of MRI with Serum Lectin-Reactive Alpha-Fetoprotein for Liver Cancer Recurrence after Percutaneous Radiofrequency Ablation. Evidence-Based Complementary and Alternative Medicine 2022; 2022 doi: 10.1155/2022/5132135
|
| 67 |
Haohao Lu, Chuansheng Zheng, Bin Liang, Bin Xiong. Mechanism and risk factors of nausea and vomiting after TACE: a retrospective analysis. BMC Cancer 2021; 21(1) doi: 10.1186/s12885-021-08253-1
|
| 68 |
Dandan Bai, Xiaobing Zhang, Yuhui Lai. Multimodal procedural sedation and analgesia in TACE for HCC: Impact on pain and hospital stay. Journal of Radiation Research and Applied Sciences 2026; 19(2) doi: 10.1016/j.jrras.2026.102431
|
| 69 |
Jian Huang, Fu-Chen Liu, Yun Yang, Sheng-Xian Yuan, Fang-Ming Gu, Bei-Ge Jiang, Ze-Ya Pan. Comparative Performance of Stereotactic Body Radiotherapy and Lenvatinib in Unresectable Hepatocellular Carcinoma Complicated by Portal Vein Tumor Thrombosis: A Propensity Score-Matched Cohort Analysis. Journal of Hepatocellular Carcinoma 2026; doi: 10.2147/JHC.S589137
|
| 70 |
Seona M. Rossi, Timothy Murray, Liam McDonough, Helena Kelly. Loco-regional drug delivery in oncology: current clinical applications and future translational opportunities. Expert Opinion on Drug Delivery 2021; 18(5) doi: 10.1080/17425247.2021.1856074
|
| 71 |
Yan-Xin Wan, Zhen-Yi Lin, Lin-Tao Chen, Rong-Qian Wu, Yu Zhang, Zhao-Qing Du. Arterial and biliary complications after transarterial chemoembolization for hepatocellular carcinoma. World Journal of Clinical Oncology 2026; 17(1): 113618 doi: 10.5306/wjco.v17.i1.113618
|
| 72 |
Kichang Han, Jin Hyoung Kim, Gi-Young Ko, Dong Il Gwon, Kyu-Bo Sung. Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: A comprehensive review. World Journal of Gastroenterology 2016; 22(1): 407-416 doi: 10.3748/wjg.v22.i1.407
|
| 73 |
Tetsushi MIZUTANI, Mizuo HASHIMOTO, Hiroaki USUI, Tomoki KOBAYASHI, Motonobu NISHIMURA, Kenji SAKAGUCHI. Complete Pathological Response of Hepatocellular Carcinoma with Portal Vein Thrombosis Treated with Sorafenib—Report of a Case—. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association) 2021; 82(3) doi: 10.3919/jjsa.82.635
|
| 74 |
Wenying Qiao, Qi Wang, Tingting Mei, Qi Wang, Wen Wang, Yonghong Zhang. External validation and improvement of the scoring system for predicting the prognosis in hepatocellular carcinoma after interventional therapy. Frontiers in Surgery 2023; 10 doi: 10.3389/fsurg.2023.1045213
|
| 75 |
Wen-Sheng Tzeng, Wei-Lin Teng, Pao-Hsien Huang, Tzu-Ching Lin, Feng-Lin Yen, Yow-Ling Shiue. Pterostilbene Nanoparticles Downregulate Hypoxia-Inducible Factors in Hepatoma Cells Under Hypoxic Conditions. International Journal of Nanomedicine 2021; doi: 10.2147/IJN.S282172
|
| 76 |
Cailing Ye, Yaqiong Chen, Jiahao Chen, Zhongcheng Chen, Wensi Chen, Suqing Zhao, Bo Hu, Zhaoxia Li. Prognostic Value of a Novel Model for Hepatocellular Carcinoma Patients Undergoing Transarterial Chemoembolization. Journal of Clinical Laboratory Analysis 2025; 39(19) doi: 10.1002/jcla.70095
|
| 77 |
Ze-Feng Zhang, Yu-Jun Luo, Quan Lu, Shi-Xue Dai, Wei-Hong Sha. Conversion therapy and suitable timing for subsequent salvage surgery for initially unresectable hepatocellular carcinoma: What is new?. World Journal of Clinical Cases 2018; 6(9): 259-273 doi: 10.12998/wjcc.v6.i9.259
|
| 78 |
Xin Li, Yaxi Wang, Xin Ye, Ping Liang. Locoregional Combined With Systemic Therapies for Advanced Hepatocellular Carcinoma: An Inevitable Trend of Rapid Development. Frontiers in Molecular Biosciences 2021; 8 doi: 10.3389/fmolb.2021.635243
|
| 79 |
Rie Sugimoto, Miho Kurokawa, Yuki Tanaka, Takeshi Senju, Motoyuki Kohjima, Masatake Tanaka. Advances in Systemic Therapy for Hepatocellular Carcinoma and Future Prospects. Current Oncology 2025; 32(9) doi: 10.3390/curroncol32090490
|
| 80 |
Tomoyuki Suehiro, Hisamitsu Miyaaki, Yasuko Kanda, Hidetaka Shibata, Takuya Honda, Eisuke Ozawa, Satoshi Miuma, Naota Taura, Kazuhiko Nakao. Serum exosomal microRNA‑122 and microRNA‑21 as predictive biomarkers in transarterial chemoembolization‑treated hepatocellular carcinoma patients. Oncology Letters 2018; doi: 10.3892/ol.2018.8991
|
| 81 |
Cong Chen, Jian Liu, Zhuxin Gu, Yanjun Sun, Wenwu Lu, Xiaokan Liu, Kang Chen, Tianzhi Ma, Suming Zhao, Hui Zhao. Integration of Multimodal Computed Tomography Radiomic Features of Primary Tumors and the Spleen to Predict Early Recurrence in Patients with Postoperative Adjuvant Transarterial Chemoembolization. Journal of Hepatocellular Carcinoma 2023; doi: 10.2147/JHC.S423129
|
| 82 |
Wen-Jie Zhou, Jin-Tao Huang, Xin Lu, Di Hu, Xin Hong, Fu-An Wang, Peng-Hua Lv, Xiao-Li Zhu. Transarterial Chemoembolization Plus Camrelizumab and Rivoceranib versus Camrelizumab and Rivoceranib Alone for BCLC Stage C Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma 2024; doi: 10.2147/JHC.S494520
|
| 83 |
Liu Yang, Long-fei Zeng, Guo-qing Hong, Qing Luo, Xing Lai, Fu Wang. Construction of a Novel Clinical Stage-Related Gene Signature for Predicting Outcome and Immune Response in Hepatocellular Carcinoma. Journal of Immunology Research 2022; 2022 doi: 10.1155/2022/6535009
|
| 84 |
Jie Li, Song Yang, Yaling Li, Chengjun Li, Yuhan Xia, Shishi Zhu, Jinglin Xia. The C-Reactive Protein to Albumin Ratio Is an Independent Prognostic Factor in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: A Large Cohort Study. CardioVascular and Interventional Radiology 2022; 45(9) doi: 10.1007/s00270-022-03208-w
|
| 85 |
Ahmed Ali Aziz, Nosheen Omar, Rehan Shah, Muhammad Ali Aziz, Ijlal Akbar Ali. Portal Venous Gas After Trans-arterial Radioembolization in Hepatocellular Carcinoma: A Rare but Critical Imaging Finding. Cureus 2025; doi: 10.7759/cureus.88107
|
| 86 |
Roberto Iezzi, Tiago Bilhim, Laura Crocetti, Bora Peynircioglu, Shraga Goldberg, Josè Ignacio Bilbao, Ahmed Sami, Okan Akhan, Paola Scalise, Felice Giuliante, Maurizio Pompili, Vincenzo Valentini, Antonio Gasbarrini, Cesare Colosimo, Riccardo Manfredi. “Primum Non Nocere” in Interventional Oncology for Liver Cancer: How to Reduce the Risk for Complications?. Life 2020; 10(9) doi: 10.3390/life10090180
|
| 87 |
Alessandro Rizzo, Angela Dalia Ricci, Giovanni Brandi. Trans-Arterial Chemoembolization Plus Systemic Treatments for Hepatocellular Carcinoma: An Update. Journal of Personalized Medicine 2022; 12(11) doi: 10.3390/jpm12111788
|
| 88 |
Ligang Chen, Yifei Zheng, Hongjian Zhang, Heng Pan, Qiusong Liu, Xu Zhou, Wei Wei, Yun Liu, Maochuan Zhen, Jinling Wang, Jianyin Zhou, Yilin Zhao. Comparative analysis of tumor‑associated vascular changes following TACE alone or in combination with sorafenib treatment in HCC: A retrospective study. Oncology Letters 2018; doi: 10.3892/ol.2018.9055
|
| 89 |
Apichat Kaewdech, Pimsiri Sripongpun, Suraphon Assawasuwannakit, Panu Wetwittayakhlang, Sawangpong Jandee, Naichaya Chamroonkul, Teerha Piratvisuth. FAIL-T (AFP, AST, tumor sIze, ALT, and Tumor number): a model to predict intermediate-stage HCC patients who are not good candidates for TACE. Frontiers in Medicine 2023; 10 doi: 10.3389/fmed.2023.1077842
|
| 90 |
Tzu-Ping Chien, Song-Fong Huang, Wen-Hui Chan, Kuang-Tse Pan, Ming-Chin Yu, Wei-Chen Lee, Hsin-I Tsai, Po-Ting Lin, Hsing-Yu Chen, Jui-Hsuan Chen, Chao-Wei Lee. The combination of sarcopenia and biochemical factors can predict the survival of hepatocellular carcinoma patients receiving transarterial chemoembolization. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.1005571
|
| 91 |
Jinpeng Li, Yan Li, Jinlong Song, Lujun Zhao. Efficacy and Safety Analysis of Transarterial Chemoembolization Plus Donafenib With or Without Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma: A Prospective, Single-Arm, Single-Center, Phase II Clinical Study. Journal of Hepatocellular Carcinoma 2024; doi: 10.2147/JHC.S473617
|
| 92 |
Shou Wu Lee, Chun Fang Tung, Yen Chun Peng, Han Chung Lien, Chi Sen Chang. Therapeutic benefits of combined sorafenib for intermediate hepatocellular carcinoma unresponsive to transarterial chemoembolization in a Chinese population. Journal of Digestive Diseases 2020; 21(8) doi: 10.1111/1751-2980.12911
|
| 93 |
Liyun Zheng, Shiji Fang, Fazong Wu, Weiqian Chen, Minjiang Chen, Qiaoyou Weng, Xulu Wu, Jingjing Song, Zhongwei Zhao, Jiansong Ji. Efficacy and Safety of TACE Combined With Sorafenib Plus Immune Checkpoint Inhibitors for the Treatment of Intermediate and Advanced TACE-Refractory Hepatocellular Carcinoma: A Retrospective Study. Frontiers in Molecular Biosciences 2021; 7 doi: 10.3389/fmolb.2020.609322
|
| 94 |
Yong Liang, Zhen Liu, Dongliang Zuo, Shi Chen, Jianbin Chen, Xiaowen Yan, Pingguo Liu, Qiuquan Wang. Single cell glycan-linkages profiling for hepatocellular carcinoma early diagnosis using lanthanide encoded bacteriophage MS2 based ICP-MS. Talanta 2024; 274 doi: 10.1016/j.talanta.2024.126056
|
| 95 |
Andreea-Elena Scheau, Sandra Oana Jurca, Cristian Scheau, Ioana Gabriela Lupescu. Non-Surgical Treatment for Hepatocellular Carcinoma: What to Expect at Follow-Up Magnetic Resonance Imaging—A Pictorial Review. Applied Sciences 2024; 14(20) doi: 10.3390/app14209159
|
| 96 |
Jiaxi Liu, Peng Wang, Liqi Shang, Zhoubo Zhang, Yulong Tian, Xiaowei Chen, Yanan Ma, Haibo Shao. TACE plus tyrosine kinase inhibitors and immune checkpoint inhibitors versus TACE plus tyrosine kinase inhibitors for the treatment of patients with hepatocellular carcinoma: a meta-analysis and trial sequential analysis. Hepatology International 2024; 18(2) doi: 10.1007/s12072-023-10591-0
|
| 97 |
Jihye Lim, Kyung Won Kim, Yousun Ko, Il-Young Jang, Yung Sang Lee, Young-Hwa Chung, Han Chu Lee, Young-Suk Lim, Kang Mo Kim, Ju Hyun Shim, Jonggi Choi, Danbi Lee. The role of muscle depletion and visceral adiposity in HCC patients aged 65 and over undergoing TACE. BMC Cancer 2021; 21(1) doi: 10.1186/s12885-021-08905-2
|
| 98 |
Namita E. Mathew, Mohammad Elsayed, Nariman Nezami, Bill S. Majdalany, Ripal Gandhi, Michael Haber, Zachary L. Bercu, Nima Kokabi. Systematic Review of Radiation-Based Therapies for Hepatocellular Carcinoma. Digestive Disease Interventions 2021; 5(02) doi: 10.1055/s-0041-1728807
|
| 99 |
Shuiying Tang, Bihong Xu, Huajin Pang, Lijun Xiao, Quelin Mei, Xiaofeng He. Ozonated Water Inhibits Hepatocellular Carcinoma Invasion and Metastasis by Regulating the HMGB1/NF-κB/STAT3 Signaling Pathway. Journal of Hepatocellular Carcinoma 2023; doi: 10.2147/JHC.S394074
|
| 100 |
Xiu-Bei Wang, Ling-Fang Sun, Mei-E Niu, Jian-Zheng Cai, Hai-Fang Wang. The Effect of Nursing Management of Patients Undergoing Interventional Therapy for Liver Cancer Compared with Standard Care on Patient-Reported Outcomes. Clinical Nursing Research 2022; 31(6) doi: 10.1177/10547738221090556
|
| 101 |
Shibo Fu, Fan Sun, Jiaxu Yang, Shaowei Zhang, Yukui Lian, Lifen Jiang. Clinical Risk Predication for Hepatocellular Carcinoma Based on Swin Transformer. Proceedings of the 2023 2nd International Conference on Algorithms, Data Mining, and Information Technology 2023; doi: 10.1145/3625403.3625448
|
| 102 |
Ying Zhao, Nan Wang, Jingjun Wu, Qinhe Zhang, Tao Lin, Yu Yao, Zhebin Chen, Man Wang, Liuji Sheng, Jinghong Liu, Qingwei Song, Feng Wang, Xiangbo An, Yan Guo, Xin Li, Tingfan Wu, Ai Lian Liu. Radiomics Analysis Based on Contrast-Enhanced MRI for Prediction of Therapeutic Response to Transarterial Chemoembolization in Hepatocellular Carcinoma. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.582788
|
| 103 |
Haoran Huo, Xiaoying Wang, Shan Xu, Xiaotong Niu, Limin Cheng, Zengjiang Yuan, Shuang Huo, Pingping Fang. Transarterial chemoembolization plus camrelizumab is an effective and tolerable bridging therapy for patients with intermediate‑stage hepatocellular carcinoma: A pilot study. Oncology Letters 2023; 26(5) doi: 10.3892/ol.2023.14052
|
| 104 |
Hongyao Chen, Renyi Yang, Xiaopeng Yu, Kexiong Li, Peisen Xue, Wei Peng, Puhua Zeng. Development of a Nomogram Using the Inflammatory Risk Score for Prognostication in Moderate and Advanced Hepatocellular Carcinoma Associated with Hepatitis B Virus. Balkan Medical Journal 2024; doi: 10.4274/balkanmedj.galenos.2024.2023-12-8
|
| 105 |
Ah Ran Kim, Eugene Park, So Young Kwon, Seong Jun Park, Young Jung Kim, Byung Chul Yoo, Won Hyeok Choe, Jeong Han Kim, Jin Ho Hwang, Sang Woo Park, Young Jun Kim, Hee Sun Park, Mi hye Yu, Hae jeong Jeon. Efficacy and Safety of Combined Radiofrequency Ablation with Transarterial Chemoembolization in Patients with Barcelona Clinic Liver Cancer Stage A Hepatocellular Carcinoma Ineligible for Curative Treatment. The Korean Journal of Gastroenterology 2019; 73(3) doi: 10.4166/kjg.2019.73.3.167
|
| 106 |
Jayoung Lee, Eunyoung E. Suh. The Effect of P6 Acupressure on Nausea, Vomiting and Retching of Patients with Liver Cancer Undergoing Transcatheter Arterial Chemoembolization (TACE) Using Nonequivalent Control Group Non-synchronized Design. Asian Oncology Nursing 2024; 24(4) doi: 10.5388/aon.2024.24.4.216
|
| 107 |
Anubhav Harish Khandelwal, Amar Mukund, Arun Gupta, Dayananda Lingegowda, Jagadeesh Singh, Madhu Prashanth, Naveen Kalra, Reddi Prasad Yadavali, Sanjeeva Prasad Kalva, Satheesh Ramamurthy, Shivanand Gamanagatti, Shuvro Roy Choudhury, Shyamkumar Nidugala Keshava, Surabhi Jajodia, Suyash Kulkarni, Jin Wook Chung, Sanjay Saran Baijal. Consensus Practice Guidelines for Conventional Transarterial Chemoembolization (cTACE) in the Treatment of Hepatocellular Carcinoma. Journal of Clinical Interventional Radiology ISVIR 2026; doi: 10.1055/s-0045-1815730
|
| 108 |
Julia Wagenpfeil, Patrick Arthur Kupczyk, Philipp Bruners, Robert Siepmann, Emelie Guendel, Julian Alexander Luetkens, Alexander Isaak, Carsten Meyer, Fabian Kuetting, Claus Christian Pieper, Ulrike Irmgard Attenberger, Daniel Kuetting. Outcome of transarterial radioembolization in patients with hepatocellular carcinoma as a first-line interventional therapy and after a previous transarterial chemoembolization. Frontiers in Radiology 2024; 4 doi: 10.3389/fradi.2024.1346550
|
| 109 |
Bufu Tang, Jiaqi Yang, Wangting Xu, Guangzhi Wang, Weishi Ye, Changyu Li, Juncheng Wan, Yongjie Zhou, Caihong Yu, Chaoqiao Jin, Zhiping Yan, Xudong Qu, Wen Zhang. Interventional therapy for hepatocellular carcinoma in the immunotherapy era: From mechanism exploration to materials innovation. Biomaterials 2026; 333 doi: 10.1016/j.biomaterials.2026.124208
|
| 110 |
Po-Da Chen, Chiung-Nien Chen, Rey-Heng Hu, Hong-Shiee Lai. Clinical experience of double primary gastric cancer and hepatocellular carcinoma. Formosan Journal of Surgery 2017; 50(1) doi: 10.4103/fjs.fjs_9_17
|
| 111 |
Lu Zhang, Zhe Jin, Chen Li, Zicong He, Bin Zhang, Qiuying Chen, Jingjing You, Xiao Ma, Hui Shen, Fei Wang, Lingeng Wu, Cunwen Ma, Shuixing Zhang. An interpretable machine learning model based on contrast-enhanced CT parameters for predicting treatment response to conventional transarterial chemoembolization in patients with hepatocellular carcinoma. La radiologia medica 2024; 129(3) doi: 10.1007/s11547-024-01785-z
|
| 112 |
Kazuo Tarao, Akito Nozaki, Hirokazu Komatsu, Tatsuji Komatsu, Masataka Taguri, Katsuaki Tanaka, Makoto Chuma, Kazushi Numata, Shin Maeda. Real impact of tumor marker AFP and PIVKA-II in detecting very small hepatocellular carcinoma (≤ 2 cm, Barcelona stage 0) - assessment with large number of cases. World Journal of Hepatology 2020; 12(11): 1046-1054 doi: 10.4254/wjh.v12.i11.1046
|
| 113 |
Aleksandar Filipović, Dragan Mašulović, Danijel Galun. Transarterial chemoembolization in hepatocellular carcinoma treatment during the COVID-19 pandemic. Medicinski podmladak 2024; 75(2) doi: 10.5937/mp75-44652
|
| 114 |
Long-Wang Lin, Kun Ke, Le-Ye Yan, Rong Chen, Jing-Yao Huang. Efficacy and safety of hepatic artery infusion chemotherapy combined with tyrosine kinase inhibitors plus programmed death-1 inhibitors for hepatocellular carcinoma refractory to transarterial chemoembolization. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1178428
|
| 115 |
Xiao-Lu Ma, Jia-Ye Zhou, Xing-Hui Gao, Lu Tian, Jiong Wu, Chun-Yan Zhang, Yan Zhou, Qian Dai, Bei-Li Wang, Bai-Shen Pan, Xin-Rong Yang, Wei Guo. Application of the albumin-bilirubin grade for predicting prognosis after curative resection of patients with early-stage hepatocellular carcinoma. Clinica Chimica Acta 2016; 462 doi: 10.1016/j.cca.2016.08.005
|
| 116 |
Qifan He, Jian Yang, Yonghai Jin. Development and Validation of TACE Refractoriness-Related Diagnostic and Prognostic Scores and Characterization of Tumor Microenvironment Infiltration in Hepatocellular Carcinoma. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.869993
|
| 117 |
Raphaël Bacquet, Marco Dioguardi Burgio, Jules Gregory, Mohamed Bouattour, François Cauchy, Lucas Raynaud, Luisa Paulatto, Rachida Lebtahi, Valerie Vilgrain, Maxime Ronot. The Safety and Effectiveness of Hepatic Transarterial Embolic Locoregional Therapy in Patients with Contraindications to Hepatectomy after Portal Vein Embolization. Journal of Vascular and Interventional Radiology 2023; 34(8) doi: 10.1016/j.jvir.2023.04.016
|
| 118 |
Qi Liu, Xin Xu, Wei Sun. Down-regulated HSA_circ_0003528 inhibits hepatocellular carcinoma aggressiveness via the miR-212-3p/XIAP axis. Bioengineered 2022; 13(4) doi: 10.1080/21655979.2022.2066046
|
| 119 |
Miao-Ling Chen, Chun-Xue Wu, Jian-Bo Zhang, Hao Zhang, Yuan-Dong Sun, Shi-Lin Tian, Jian-Jun Han. Transarterial chemoembolization combined with metformin improves the prognosis of hepatocellular carcinoma patients with type 2 diabetes. Frontiers in Endocrinology 2022; 13 doi: 10.3389/fendo.2022.996228
|
| 120 |
Dong-Jun Son, Ji-Yun Hong, Ki-Hyun Kim, Young-Hoon Jeong, Dae-Seong Myung, Sung-Bum Cho, Wan-Sik Lee, Yang-Jun Kang, Jin-Woong Kim, Young-Eun Joo. Liver abscess caused by Clostridium haemolyticum infection after transarterial chemoembolization for hepatocellular carcinoma. Medicine 2018; 97(19) doi: 10.1097/MD.0000000000010688
|
| 121 |
Xing Chen, Yuhong Ma, Jun Zhang, Wei Yang, Chengbing Jin, Lifeng Ran, Hui Zhu, Jin Bai, Kun Zhou. Evaluating the long-term survival benefits of high intensity focused ultrasound ablation for hepatocellular carcinoma with portal vein tumor thrombus: a single center retrospective study. International Journal of Hyperthermia 2022; 39(1) doi: 10.1080/02656736.2022.2122595
|
| 122 |
A. Fohlen, J.P. Tasu, H. Kobeiter, J.M. Bartoli, J.P. Pelage, B. Guiu. Transarterial chemoembolization (TACE) in the management of hepatocellular carcinoma: Results of a French national survey on current practices. Diagnostic and Interventional Imaging 2018; 99(9) doi: 10.1016/j.diii.2018.03.003
|
| 123 |
Shih-Wei Yang, Wei-Liang Chen, Wei-Te Wu, Chung-Ching Wang. Investigation on returning to work in liver cancer survivors in Taiwan: a 5-year follow-up study. BMC Public Health 2021; 21(1) doi: 10.1186/s12889-021-11872-9
|
| 124 |
Yutaka Yasui, Kaoru Tsuchiya, Masayuki Kurosaki, Takaya Takeguchi, Yuko Takeguchi, Mao Okada, Wan Wang, Yohei Kubota, Tomoyuki Goto, Yasuyuki Komiyama, Mayu Higuchi, Kenta Takaura, Tsuguru Hayashi, Hitomi Takada, Nobuharu Tamaki, Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi, Yasuhiro Asahina, Nobuyuki Enomoto, Yoshiro Himeno, Namiki Izumi. Up‐to‐seven criteria as a useful predictor for tumor downstaging to within Milan criteria and Child–Pugh grade deterioration after initial conventional transarterial chemoembolization. Hepatology Research 2018; 48(6) doi: 10.1111/hepr.13048
|
| 125 |
Heesoon Sheen, Jin Sil Kim, Jeong Kyong Lee, Sun Young Choi, Seung Yon Baek, Jung Young Kim. A radiomics nomogram for predicting transcatheter arterial chemoembolization refractoriness of hepatocellular carcinoma without extrahepatic metastasis or macrovascular invasion. Abdominal Radiology 2021; 46(6) doi: 10.1007/s00261-020-02884-x
|
| 126 |
Yu Zhou, Wanrui Wu, Wei Cai, Dong Zhang, Weiwei Zhang, Yunling Luo, Fujing Cai, Zhenjing Shi. Prognostic prediction using a gene signature developed based on exhausted T cells for liver cancer patients. Heliyon 2024; 10(6) doi: 10.1016/j.heliyon.2024.e28156
|
| 127 |
Wei Jing, Ruoyu Peng, Xiaogai Li, Shaogang Lv, Yu Duan, Shitao Jiang, Fu Wang. Study on the Prognostic Values of TTC36 Correlated with Immune Infiltrates and Its Methylation in Hepatocellular Carcinoma. Journal of Immunology Research 2022; 2022 doi: 10.1155/2022/7267131
|
| 128 |
Lior Charach, Lior Zusmanovitch, Gideon Charach. Hepatocellular Carcinoma. Part 2: Clinical Presentation and Diagnosis. EMJ Hepatology 2017; doi: 10.33590/emjhepatol/10311703
|
| 129 |
Haohao Lu, Bin Liang, Chuansheng Zheng, Xiangwen Xia. Comparative analysis of efficacy and safety between D-TACE + HAIC + lenvatinib and D-TACE + lenvatinib in the treatment of unresectable massive hepatocellular carcinoma. BMC Cancer 2024; 24(1) doi: 10.1186/s12885-024-13179-5
|
| 130 |
Gang Yuan, Zhiyin Liu, Weiming Wang, Mengnan Liu, Yanneng Xu, Wei Hu, Yao Fan, Xun Zhang, Yong Liu, Guangyan Si. Multifunctional nanoplatforms application in the transcatheter chemoembolization against hepatocellular carcinoma. Journal of Nanobiotechnology 2023; 21(1) doi: 10.1186/s12951-023-01820-7
|
| 131 |
Daniel J. Boehmler, Ryan J. Baron, Jennifer A. Brain, Ariful Islam, Yohan Kim, Alexey Gurevich, Nicholas R. Perkons, Alexander I. Zavriyev, Rudra Amin, Jessica Andrew-Udoh, Erena Tuzneen Supan, Ryan El Ghazal, Stephen J. Hunt, George McClung, David Tischfield, Daniel Ackerman, Aalim M. Weljie, Kelley Weinfurtner, Nicolas Skuli, Terence P.F. Gade. Locoregional lactate dehydrogenase inhibition potentiates therapy and overcomes treatment resistance in hepatocellular carcinoma. Hepatology 2026; doi: 10.1097/HEP.0000000000001775
|
| 132 |
Nam Hee Kim, Hong Joo Kim, Yong Kyun Cho, Hyun Pyo Hong, Byung Ik Kim. Long-Term Efficacy and Safety of Partial Splenic Embolization in Hepatocellular Carcinoma Patients with Thrombocytopenia Who Underwent Transarterial Chemoembolization. Journal of Korean Medical Science 2019; 34(30) doi: 10.3346/jkms.2019.34.e208
|
| 133 |
Ming Fang Hsu, Yen Sheng Tyan, Yu Chen Chien, Ming Wei Lee. Hyaluronic acid-based nano-sized drug carrier-containing Gellan gum microspheres as potential multifunctional embolic agent. Scientific Reports 2018; 8(1) doi: 10.1038/s41598-018-19191-7
|
| 134 |
Enas M. Sweed, Maha S. Moustafa, Ashraf S. Shafei, Tamer A. Kamal, Wessam M. Abdlelatif. Value of computed tomography-based lipiodol retention pattern in the assessment of hepatocellular carcinoma complete response following conventional transarterial chemoembolization. Egyptian Journal of Radiology and Nuclear Medicine 2024; 55(1) doi: 10.1186/s43055-024-01187-1
|
| 135 |
Maheen Bhangwar Baloch, Chris Alphonse, Nehal Baldev, Genesis Marie Nin-Arroyo, Rohith Keezhath, Anahita Behara, Swati Khurana, Stephanie Nwokeji, Bashir Imam, Yozahandy A Abarca-Pineda. Cardiovascular Risk in Autoimmune Diseases: Mechanisms, Management, and Emerging Evidence. Cureus 2025; doi: 10.7759/cureus.91897
|
| 136 |
Naisarg B Vanani, Abhishek Janardan, Nisar Asmi, Pinky Jha. Post-embolization Syndrome Following Yttrium-90 Radiation Segmentectomy. Cureus 2023; doi: 10.7759/cureus.35947
|
| 137 |
Lin Zheng, Chen-Yang Guo, Cheng-Shi Chen, Jin-Cheng Xiao, Hong-Tao Hu, Hong-Tao Cheng, Deng-Wei Zong, Li Jiang, Hai-Liang Li. Sorafenib improves lipiodol deposition in transarterial chemoembolization of Chinese patients with hepatocellular carcinoma: a long-term, retrospective study. Oncotarget 2017; 8(57) doi: 10.18632/oncotarget.18811
|
| 138 |
T. J. Vogl, M. C. Langenbach, R. Hammerstingl, M. H. Albrecht, A. R. Chatterjee, T. Gruber-Rouh. Evaluation of two different transarterial chemoembolization protocols using Lipiodol and degradable starch microspheres in therapy of hepatocellular carcinoma: a prospective trial. Hepatology International 2021; 15(3) doi: 10.1007/s12072-021-10193-8
|
| 139 |
Nisha Manjunatha, Vinutna Ganduri, Kruthiga Rajasekaran, Shrimahitha Duraiyarasan , Mayowa Adefuye. Transarterial Chemoembolization and Unresectable Hepatocellular Carcinoma: A Narrative Review. Cureus 2022; doi: 10.7759/cureus.28439
|
| 140 |
Taro Mizuno, Takayuki Goto, Kota Shimojo, Naoki Watanabe, Takuji Tanaka. Clinical Utility of Tumor Markers. Open Journal of Pathology 2021; 11(02) doi: 10.4236/ojpathology.2021.112005
|
| 141 |
Qingyu Xu, Chendong Wang, Guowen Yin. Immune-related gene signature to predict TACE refractoriness in patients with hepatocellular carcinoma based on artificial neural network. Frontiers in Genetics 2023; 13 doi: 10.3389/fgene.2022.993509
|
| 142 |
Shuguang Ju, Wenhui Wang, Pengfei Chen, Fangzheng Li, Hao Li, Manzhou Wang, Xinwei Han, Jianzhuang Ren, Xuhua Duan. Drug-eluting bead transarterial chemoembolization followed by apatinib is effective and safe in treating hepatocellular carcinoma patients with BCLC stage C. Clinics and Research in Hepatology and Gastroenterology 2022; 46(3) doi: 10.1016/j.clinre.2022.101859
|
| 143 |
Pengkai Ma, Jianhua Chen, Haixian Qu, Ye Li, Xiaohui Li, Xuemei Tang, Zhigang Song, Hainan Xin, Jinbang Zhang, Jingxue Nai, Zhiping Li, Zhijun Wang. Hypoxic targeting and activating TH-302 loaded transcatheter arterial embolization microsphere. Drug Delivery 2020; 27(1) doi: 10.1080/10717544.2020.1831102
|
| 144 |
Yan Miao, Ying Zhang, Lihong Yin. Trends in hepatocellular carcinoma research from 2008 to 2017: a bibliometric analysis. PeerJ 2018; 6 doi: 10.7717/peerj.5477
|
| 145 |
Weijia Wang, Behishta Hashimi, Ping Wang. Targeting ferroptosis: the role of non-coding RNAs in hepatocellular carcinoma progression and therapy. Naunyn-Schmiedeberg's Archives of Pharmacology 2025; 398(6) doi: 10.1007/s00210-025-03791-y
|
| 146 |
Qiang Wang, Maocai Tang, Shouru Zhang. Comparison of radiofrequency ablation and surgical resection for hepatocellular carcinoma conforming to the Milan criteria: a meta‐analysis. ANZ Journal of Surgery 2021; 91(7-8) doi: 10.1111/ans.16560
|
| 147 |
Cheng Yan, Yandie Niu, Liukai Ma, Lifang Tian, Jiahao Ma. System analysis based on the cuproptosis-related genes identifies LIPT1 as a novel therapy target for liver hepatocellular carcinoma. Journal of Translational Medicine 2022; 20(1) doi: 10.1186/s12967-022-03630-1
|
| 148 |
Kota Takaki, Masahito Nakano, Kazuta Fukumori, Yoichi Yano, Yuki Zaizen, Takashi Niizeki, Kotaro Kuwaki, Masaru Fukahori, Takahiko Sakaue, Sohei Yoshimura, Mika Nakazaki, Takuji Torimura. Percutaneous Radiofrequency Ablation with or without Chemolipiodolization for Hepatocellular Carcinoma: A Propensity-Score-Matched Analysis. Journal of Clinical Medicine 2022; 11(6) doi: 10.3390/jcm11061483
|